Neogen Chemicals has closed a Qualified Institutions Placement (QIP) — a fundraise sold only to large institutions — allotting 26,60,753 new shares at ₹2,255 each to raise ₹599.99 crore. The company told the exchanges on 17 September 2026 that its Fund-Raising Committee approved the allotment late on 16 September, closing an issue open since 10 September.

What was announced

• Issued: 26,60,753 shares of ₹10 face value at ₹2,255 (₹2,245 premium)
• Floor price: ₹2,189.73 — shares went out 2.98% above the minimum SEBI's formula allowed, not at a deeper discount
• Raised: ₹5,99,99,98,015 — call it ₹600 crore
• Share count: rises from 2,73,81,674 to 3,00,42,427
• Buyers above 5%: ICICI Prudential, Invesco India and Mirae Asset funds

Stated use of proceeds: repaying or pre-paying borrowings, long-term working capital, and general corporate purposes. The board approved the plan on 24 July 2026; shareholders cleared it on 21 August 2026.

What a QIP actually is

A QIP is the fastest legal route for a listed Indian company to raise fresh equity. Rather than a public issue with a prospectus, it sells new shares straight to Qualified Institutional Buyers — mutual funds, insurers, pension funds, FPIs. Retail investors cannot participate.

The protection for existing shareholders is the floor price: SEBI's ICDR rules compute a minimum from a recent traded average, below which the company may not price without extra approval. Here the floor was ₹2,189.73, about 8.25% under the ₹2,386.55 close before launch. Neogen priced above it at ₹2,255 — roughly 5.5% below that close. Pricing above floor usually signals a comfortably covered book; weak demand pushes a deal to the floor or below.

Why it matters

Dilution is the cost. The new shares are 8.86% of the enlarged capital — someone who owned 1.00% now owns about 0.91% without selling anything. Profit is divided across 9.7% more shares, so earnings must grow about that much just to hold EPS flat.

The balance sheet is the benefit. Neogen carried ₹1,395 crore of borrowings as of March 2026 against roughly ₹75 crore of annual interest cost, and Screener flags a low interest-coverage ratio. The ₹600 crore raised is about 43% of that debt. To the extent it retires borrowings, interest expense falls — the trade many companies mid-capex make consciously: accept permanent dilution to remove a financing risk.

Valuation, as reported

Neogen trades on a trailing P/E of about 178 on consolidated numbers (Screener, 15 September 2026), at a market cap near ₹6,326 crore and P/B 7.47x, ROCE 6.46%, ROE 3.58%. Against its own history, GuruFocus puts the 10-year median at 80.4, with year-end readings of 102 (FY22), 117 (FY23), 85 (FY24), 64 (FY25) and 93 (FY26). The closest bromine peer by size, Archean Chemical Industries, trades near P/E 58.8 at about ₹5,697 crore market cap and P/B 2.94. The high P/E reflects depressed earnings as much as price — profit compounded 8% over five years against 21% sales growth. Reported figures, not a view on the price.

The business

Neogen makes bromine-based and lithium-based specialty chemicals, organic and inorganic, feeding pharmaceuticals, agrochemicals and engineering applications. Its newer push is battery materials — electrolytes and lithium salts for the Li-ion chain — where much of the recent capex has gone. FY26 revenue was about ₹862 crore; Q1 FY27 revenue rose 34% year-on-year to ₹250.29 crore with net profit up 66.76% to ₹17.11 crore. A QIP is a company-wide balance-sheet event, not confined to one division.

Beginner takeaway

A completed QIP is neither good nor bad by itself — it is a swap. Shareholders give up a slice of ownership (8.86% here) and the company gets cash it never repays. Whether it works depends on what the cash does: retiring expensive debt mid-capex is very different from plugging an operating hole. Watch the interest-cost line over the next few quarters.

FAQ

Could I have bought shares in this QIP? No. QIPs are open only to Qualified Institutional Buyers such as mutual funds and insurers. Retail investors can buy only later, on the open market.

Do I lose money from the dilution? You lose proportional ownership, not automatically value — the company gained ₹600 crore, so the pie is bigger even as your slice thins.

Do the new shares get dividends? Yes. The filing states they rank pari passu with existing shares in all respects, including dividends and voting rights.

Related: a surprise $2bn share sale, funding a ₹820 crore capex plan, and a specialty-chemicals re-rating.

As of 17 September 2026. Source: official BSE/NSE filing — read it directly here. We summarise filings for education and may make errors, so always verify against the official document. Educational content only — not investment advice, not a buy/sell recommendation.